The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche\u2019s atezolizumab plus bevacizumab, Bristol Myers Squibb\u2019s nivolumab plus ipilimumab, AstraZeneca\u2019s durvalumab with or without tremelimumab, and Merck & Co.\u2019s pembrolizumab have added to the treatment armamentarium. Nevertheless, significant unmet need remains, especially in the underserved early-stage setting. We anticipate the entry of immune checkpoint inhibitor-based combinations and the label expansion of existing agents into the early-stage hepatocellular carcinoma setting, expanding treatment options and fueling further sales growth.<\/p>\n
Questions answered<\/strong><\/p>\n Geography: <\/strong>United States, EU5, Japan.<\/p>\n Primary research: <\/strong>19 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n Epidemiology: <\/strong>Diagnosed and recurrent incident cases of hepatocellular carcinoma by country, segmented by stage and line of therapy.<\/p>\n Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma therapies through 2034, segmented by brands \/ generics \/ biosimilars and epidemiological subpopulations.<\/p>\n Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies.<\/p>\n Product description<\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n